Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Audit of Veterinary Drug Retail Sales in Russia (October 2021)

Friday, November 26, 2021

From January to October 2021, the sales of veterinary drugs in the Russian retail market amounted to RUB 18.5 billion (retail prices, VAT included), up 5% from January–October 2020. The most important factor for the growth rates was the inflation rate, as well as higher demand for premium segment products in certain regions. In minimum dosage units (MDU), the growth rate was –5.1%, with the sales volume of 144 million MDUs.

The October results were not much different from those usually observed during the fall-winter season, when sales of veterinary drugs start to decline at the end of the year, which is especially noticeable against the spring and fall demands. Compared to September 2020, the sales decreased by 8.4% in monetary and by 6.8% in physical terms. Compared to October 2020, the growth rates were –0.1% in monetary and –8.7% in physical terms. That is an obvious influence of the second wave of COVID-19, which resulted in higher demand for several groups of veterinary drugs last year.

In the top 20 companies with the largest sales volumes in monetary terms, Livisto Group and Zoetis have the best growth rates among the foreign veterinary manufacturers. The sales of anthelmintic Albendazole (increased 5.3 times against January–October 2020) and non-steroidal anti-inflammatory Petcam (+54%) contributed to Livisto Group’s growth rates of +29% the most. As for Zoetis (+24%), its insectoacaricide Simparica (+39%) and antibacterial Synulox (+33%) contributed to the growth rates the most. Agrobioprom has the highest growth rates (+21%) among the Russian companies in the top 20, thanks to the sales of its sedative VetSpokoin (+47%) and ear drops Otidez (+29%).

As for the top 20 manufacturers with the largest sales volumes in physical terms, Livisto Group has the highest growth rates among the foreign companies again (+34% in MDUs). The same products that contributed to the company’s growth rates in monetary terms (Albendazole and Petcam) played the key part here. Boehringer Ingelheim is another foreign manufacturer with positive growth rates (+10%)—most companies suffered falling sales. The sales of Boehringer Ingelheim’s antiparasitic Nexgard Spectra (+45%) and cardiotonic Vetmedin (+12%) contributed to its growth rates the most. Most Russian companies in the top 20 had a decline in sales. Agrobioprom has high growth rates of +13%, together with Ekoprom (+4%). Inspector insectoacaricides and antiparasitics (+27%) and hormonal SexControl (+18%) contributed to Ekoprom’s growth rates the most.

The volume of the Russian retail market of veterinary drugs in monetary (RUB, end user prices, VAT included) and physical (MDU) terms (January 2020–October 2021)